Received: 20 January 2023
Revised: 20 March 2023
Accepted: 18 April 2023
First Online: 5 May 2023
: HKL is on the board of directors and has equity in Oncosec, is on the scientific advisory board and has equity in Replicate.
Free to read: This content has been made available to all.